Skip to main content

Table 1 Association analysis of rs2231142, rs10011796 (ABCG2) and rs11942223 (SLC2A9) in European and NZ Polynesian sample sets

From: Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout

SNPRaw NGenotype, N (%)Effect allele, N (%)Gout vs. HU*^
OR (95% CI), P
Gout vs. All Controls*
OR (95% CI), P
HU vs. NU*
OR, 95% CI, P
rs2231142 GGGTTTT   
European gout16371006 (61.5)551 (33.7)80 (7.5)711 (21.7)1.81 (1.60–2.06), 3.0E−20
1.85 (1.63–2.11), 3.8E−21
2.42 (2.18–2.68), 1.9E−64
European HU23781762 (74.1)577 (24.3)39 (1.6)655 (13.8)1.56 (1.41–1.72), 1.7E−18
European NU11,6049428 (81.2)2053 (17.7)123 (1.1)2299 (9.1) 
WP# gout36996 (26.0)189 (51.2)84 (22.8)357 (48.4)1.96 (1.30–3.00), 1.6E−03
1.77 (1.14–2.80), 0.012
2.36 (1.73–3.26), 1.1E−07
WP HU8848 (54.6)29 (33.0)11 (12.5)51 (29.0)1.52 (0.94–2.50), 0.091
WP NU14684 (57.5)52 (35.6)10 (6.9)72 (24.7)
EP# gout543436 (80.3)106 (19.5)1 (0.2)108 (9.9)1.99 (1.05–4.05), 0.044
2.02 (1.05–4.16) 0.043
2.54 (1.66–3.97), 3.4E−05
EP HU114101 (88.6)13 (11.4)0 (0.0)13 (5.7)1.41 (0.65–2.93), 0.37
EP NU348315 (90.5)32 (9.2)1 (0.3)34 (4.9) 
rs10011796 CCCTTTT   
European gout1580339 (21.5)764 (48.4)477 (30.2)1718 (54.4)1.39 (1.26–1.53), 2.0E−11
1.39 (1.26–1.53), 3.5E−11
1.55 (1.44–1.69), 1.3E−27
European HU2422666 (27.5)1208 (49.9)548 (22.6)2304 (47.6)1.18 (1.10–1.26), 7.8E−07
European NU11,9273688 (30.9)5986 (50.2)2253 (18.9)10,492 (44.0) 
WP gout36938 (10.3)163 (44.2)168 (45.5)499 (67.6)1.28 (0.86–1.91), 0.22
1.27 (0.83–1.94), 0.27
1.32 (0.99–1.77), 0.062
WP HU8810 (11.4)43 (48.9)35 (39.8)113 (64.2)1.02 (0.66–1.60), 0.92
WP NU14621 (14.4)67 (45.9)58 (39.3)183 (62.7) 
EP gout54393 (17.2)259 (47.9)189 (34.9)637 (58.9)0.94 (0.68–1.29), 0.69
0.92 (0.66–1.27), 0.60
1.03 (0.83–1.27), 0.80
EP HU11418 (15.8)51 (44.7)45 (39.5)141 (61.8)1.13 (0.81–1.57), 0.48
EP NU34867 (19.3)173 (49.7)108 (31.0)389 (55.9) 
rs11942223 TTTCCCC   
European gout15761168 (74.1)382 (24.2)26 (1.6)434 (13.8)0.72 (0.63–0.83), 2.9E−06
0.73 (0.63–0.83), 4.7E−06
0.55 (0.49–0.62), 1.4E−25
European HU24221658 (68.5)701 (28.9)63 (2.6)827 (17.1)0.66 (0.61–0.73), 2.2E−21
European NU11,9277101 (59.5)4220 (35.4)606 (5.1)5432 (22.8) 
WP gout369351 (95.1)18 (4.9)0 (0.0)18 (2.4)0.53 (0.17–2.05), 0.31
0.51 (0.15–2.08), 0.31
0.61 (0.26–1.46), 0.26
WP HU8884 (95.5)4 (4.6)0 (0.0)4 (2.3)0.83 (0.20–2.94), 0.78
WP NU146135 (92.5)11 (7.5)0 (0.0)11 (3.8) 
EP gout543501 (92.3)39 (7.2)3 (0.6)45 (4.1)1.04 (0.47–2.61), 0.92
1.24 (0.54–3.23), 0.64
1.06 (0.62–1.84), 0.84
EP HU114105 (92.1)9 (7.9)0 (0.0)9 (3.9)1.26 (0.51–12.94), 0.60
EP NU348311 (89.4)37 (10.6)0 (0.0)37 (5.3) 
  1. *European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1–10
  2. ^For Gout vs. HU analyses, the top data is before adjustment by highest recorded serum urate, and the bottom figure is after adjustment
  3. All sample sets are in Hardy-Weinberg equilibrium (P > 0.01)
  4. Polynesian meta-analysis of WP and EP Gout vs. HU, and of HU vs. NU yielded ORmeta = 1.85, P = 1.3E03., and ORmeta = 1.49, P = 0.057, respectively
  5. #WP Western Polynesian, EP Eastern Polynesian
\